D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
ATVI
Activision Blizzard Inc.
ATVI
|
+$701M |
| 2 |
Booking.com
BKNG
|
+$503M |
| 3 |
Alibaba
BABA
|
+$443M |
| 4 |
XLNX
Xilinx Inc
XLNX
|
+$389M |
| 5 |
Chipotle Mexican Grill
CMG
|
+$267M |
Top Sells
| 1 |
Apple
AAPL
|
+$1.03B |
| 2 |
Amazon
AMZN
|
+$463M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$436M |
| 4 |
Salesforce
CRM
|
+$387M |
| 5 |
Moderna
MRNA
|
+$354M |
Sector Composition
| 1 | Technology | 20.28% |
| 2 | Consumer Discretionary | 13.97% |
| 3 | Healthcare | 10.06% |
| 4 | Financials | 9.79% |
| 5 | Communication Services | 8.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3026
Yum China
YUMC
$16B
| $238K | ﹤0.01% |
4,097
-7,398
| -64% | -$430K |
|
|
RAIN
3027
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $238K | ﹤0.01% |
15,923
-11,799
| -43% | -$176K |
|
3028
Rush Street Interactive
RSI
$2.07B
| $236K | ﹤0.01% |
12,302
-38,944
| -76% | -$747K |
|
3029
Iovance Biotherapeutics
IOVA
$796M
| $235K | ﹤0.01% |
9,514
-16,072
| -63% | -$397K |
|
3030
OrthoPediatrics
KIDS
$504M
| $235K | ﹤0.01% |
+3,589
| New | +$235K |
|
3031
Liberty Global Class A
LBTYA
$4.07B
| $235K | ﹤0.01% |
7,886
-9,195
| -54% | -$274K |
|
3032
BOK Financial
BOKF
$7.19B
| $232K | ﹤0.01% |
2,590
-15,809
| -86% | -$1.42M |
|
3033
Clearwater Paper
CLW
$351M
| $232K | ﹤0.01% |
6,057
-28,581
| -83% | -$1.09M |
|
3034
Agilysys
AGYS
$3.01B
| $231K | ﹤0.01% |
4,414
-871
| -16% | -$45.6K |
|
|
BLSA
3035
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $231K | ﹤0.01% |
+23,127
| New | +$231K |
|
|
CKPT
3036
DELISTED
Checkpoint Therapeutics
CKPT
| $230K | ﹤0.01% |
6,963
-2,112
| -23% | -$69.8K |
|
3037
Genprex
GNPX
$8.18M
| $230K | ﹤0.01% |
2,144
+1,434
| +202% | +$154K |
|
3038
Avita Medical
RCEL
$150M
| $230K | ﹤0.01% |
12,966
+2,969
| +30% | +$52.7K |
|
|
VOXX
3039
DELISTED
VOXX International Corporation Class A
VOXX
| $230K | ﹤0.01% |
20,073
-21,438
| -52% | -$246K |
|
|
VRS
3040
DELISTED
Verso Corporation
VRS
| $230K | ﹤0.01% |
11,063
-22,853
| -67% | -$475K |
|
|
RCOR
3041
DELISTED
Renovacor, Inc.
RCOR
| $229K | ﹤0.01% |
25,321
| – | – |
|
3042
Farmers National Banc Corp
FMNB
$568M
| $228K | ﹤0.01% |
14,486
+68
| +0.5% | +$1.07K |
|
3043
Edgewise Therapeutics
EWTX
$1.64B
| $227K | ﹤0.01% |
13,695
-32,472
| -70% | -$538K |
|
3044
Spyre Therapeutics
SYRE
$925M
| $227K | ﹤0.01% |
1,140
-699
| -38% | -$139K |
|
3045
German American Bancorp
GABC
$1.55B
| $226K | ﹤0.01% |
+5,846
| New | +$226K |
|
3046
Integral Ad Science
IAS
$1.44B
| $225K | ﹤0.01% |
+10,924
| New | +$225K |
|
|
NPTN
3047
DELISTED
NEOPHOTONICS CORP
NPTN
| $225K | ﹤0.01% |
+25,877
| New | +$225K |
|
3048
Natural Gas Services Group
NGS
$343M
| $224K | ﹤0.01% |
21,561
-2,845
| -12% | -$29.6K |
|
3049
Origin Materials
ORGN
$79.6M
| $224K | ﹤0.01% |
32,936
-317,064
| -91% | -$2.16M |
|
|
AIFU
3050
AIFU Inc. Class A Ordinary Share
AIFU
$88.2M
| $224K | ﹤0.01% |
930
-679
| -42% | -$164K |
|